痛风患者的长期阿片类药物使用:来自退伍军人健康管理局的匹配队列研究
该匹配队列研究利用美国退伍军人健康管理局全国数据,按年龄、性别和入组年份将痛风患者与最多10名无痛风对照匹配,随访平均4.52年。痛风患者长期阿片类药物处方率为6.9%,高于对照的3.8%,校正后风险比1.30(95%CI 1.28-1.32)。在痛风患者中,较近年份、较年轻、女性、非西班牙裔黑人、农村居住、体重过低或肥胖、吸烟、更多合并症、接受降尿酸治疗及需风湿科会诊与长期阿片暴露风险升高独立相关。
要点
- 痛风患者长期阿片类药物处方率为6.9%,高于无痛风对照的3.8%。
- 校正混杂因素后,痛风与长期阿片类药物暴露风险升高独立相关(校正HR 1.30,95%CI 1.28-1.32)。
- 痛风患者中,较近诊断年份、较年轻、女性、非西班牙裔黑人、农村居住、体重异常、吸烟、更多合并症、降尿酸治疗及需风湿科会诊与风险升高相关。
核心结论
- 痛风患者比无痛风者更可能接受长期阿片类药物处方,且独立于其他因素。
- 该风险在代表性不足的痛风人群、合并症更多者、需风湿科会诊者及接受降尿酸治疗者中更高。
- 需要进一步研究以阐明优化痛风管理是否能减少痛风患者的长期阿片类药物暴露。
研究设计与样本
- 匹配队列研究,使用美国退伍军人健康管理局全国数据。
- 采用多变量Cox回归分析痛风与长期阿片类药物接收(用经验证的管理算法定义)的关联。
- 痛风患者通过诊断代码识别,按年龄、性别和VHA入组年份与最多10名无痛风对照匹配。
- 在限于痛风患者的分析中,识别与长期阿片暴露相关的因素。
主要发现
- 平均随访4.52年期间,痛风患者长期阿片类药物接收率为6.9%,无痛风对照为3.8%。
- 校正协变量后风险仍存在(校正风险比1.30;95%置信区间1.28-1.32)。
- 在痛风患者中,与长期阿片暴露风险升高独立相关的因素包括:较近的指数年份、较年轻年龄、女性、非西班牙裔黑种族和族裔、农村居住、体重过低或肥胖、既往或当前吸烟、更多合并症、接受降尿酸治疗以及需要风湿科会诊。
临床怎么用
- 原文结论指出需要进一步研究以阐明优化痛风管理是否能减少痛风患者的长期阿片类药物暴露。
局限性
- 需要进一步研究以阐明优化痛风管理是否能减少痛风患者的长期阿片类药物暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Though used frequently to treat flare, risk of long-term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long-term opioids over time. METHODS: In this matched cohort study using national Veterans Health Administration (VHA) data, multivariable Cox regression was used to examine the association of gout with long-term opioid receipt (defined using a validated administrative algorithm). Patients with gout were identified using diagnostic codes and matched with up to 10 controls without gout by age, sex, and VHA enrollment year. In analyses limited to gout, factors associated with long-term opioid exposure were identified. RESULTS: Over a mean follow-up of 4.52 years, patients with gout were more likely to receive long-term opioids than controls (6.9% vs 3.8%). This risk remained following covariate adjustment (adjusted hazard ratio 1.30; 95% confidence interval 1.28-1.32). Among patients with gout, factors independently associated with an increased likelihood of long-term opioid exposure included more recent index year, younger age, female sex, non-Hispanic Black race and ethnicity, rural residence, being underweight or obese, former or current smoking, greater comorbidity, urate-lowering therapy receipt, and requirement of rheumatology consultation. CONCLUSION: Patients with gout are more likely to receive long-term opioids than counterparts without gout, independent of other factors. This risk is greater in underrepresented gout populations, those with greater comorbidity, patients requiring rheumatology consultations, and individuals prescribed urate-lowering treatments. Additional investigation is needed to elucidate whether deployment of optimal gout management minimizes long-term opioid exposure in patients with gout.
引用
- Helget LN, England BR, Roul P, et al. Long-Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration. Arthritis Care Res (Hoboken). 2025. PMID: 40757470. doi:10.1002/acr.25622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。